Recent Advances in the Treatment of Neurodegenerative Diseases Based on GSH Delivery Systems by Cacciatore, Ivana et al.
Hindawi Publishing Corporation
Oxidative Medicine and Cellular Longevity
Volume 2012, Article ID 240146, 12 pages
doi:10.1155/2012/240146
Review Article
RecentAdvances inthe Treatmentof Neurodegenerative Diseases
BasedonGSHDeliverySystems
IvanaCacciatore,Leonardo Baldassarre,ErikaFornasari,Adriano Mollica,
andFrancesco Pinnen
Department of Drug Sciences, Faculty of Pharmacy, G. d’Annunzio University, Via dei Vestini 31, 66100 Chieti, Italy
Correspondence should be addressed to Ivana Cacciatore, cacciatore@unich.it
Received 7 February 2012; Accepted 22 March 2012
Academic Editor: Madia Trujillo
Copyright © 2012 Ivana Cacciatore et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Neurodegenerative diseases, such as Parkinson’s disease (PD) and Alzheimer’s disease(AD), are a group of pathologies
characterized by a progressive and speciﬁc loss of certain brain cell populations. Oxidative stress, mitochondrial dysfunction,
and apoptosis play interrelated roles in these disorders. It is well documented that free radical oxidative damage, particularly
on neuronal lipids, proteins, DNA, and RNA, is extensive in PD and AD brains. Moreover, alterations of glutathione (GSH)
metabolism in brain have been implicated in oxidative stress and neurodegenerative diseases. As a consequence, the reduced GSH
levels observed in these pathologies have stimulated a number of researchers to ﬁnd new potential approaches for maintaining or
restoring GSH levels. Unfortunately, GSH delivery to the central nervous system (CNS) is limited due to a poor stability and
low bioavailability. Medicinal-chemistry- and technology-based approaches are commonly used to improve physicochemical,
biopharmaceutical, and drug delivery properties of therapeutic agents. This paper will focus primarily on these approaches
used in order to replenish intracellular GSH levels, which are reduced in neurodegenerative diseases. Here, we discuss the
beneﬁcial properties of these approaches and their potential implications for the future treatment of patients suﬀering from
neurodegenerative diseases, and more speciﬁcally from PD and AD.
1.Introduction
Neurodegenerative diseases such as Alzheimer’s, Parkinson’s,
and Huntington’s diseases and amyotrophic lateral sclerosis
make up a group of pathologies characterized by a separated
etiology with distinct morphological and pathophysiological
features. These disorders are deﬁned by a multifactorial
nature and have common neuropathological hallmarks such
as (a) abnormal protein dynamics with defective protein
degradation and aggregation; (b) oxidative stress and free
radical formation; (c) impaired bioenergetics and mitochon-
drial dysfunctions; (d) neuroinﬂammatory processes [1, 2].
It is diﬃcult to establish the correct sequence of these events,
butithasbeenshownthattheoxidative damagetothebrains
of aﬀected individuals is one of the earliest pathological
markers. Oxidative and nitrosative stresses arise from the
imbalance between the increased production of both the
reactive oxygen species (ROS) and the reactive nitrogen
species (RNS) and the cellular antioxidant defense systems
[3]. At low levels, ROS function as signaling intermediates
for the modulation of cellular activities but, at higher con-
centrations, they contribute to neuronal membrane damage.
The ROS mainly involved in neurodegeneration are the
superoxide anion (O2
−), the hydrogen peroxide (H2O2), and
the hydroxyl radical (HO•). RNS, such as nitric oxide (NO),
can react with O2
− to produce peroxynitrite (ONOO−), a
powerful oxidant that may decompose itself to form HO•
[4]. Cells normally employ a number of defense mechanisms
against free radical such as enzymes (Cu/Zn- and Mn-
superoxide dismutase, GSH peroxidase, GSH reductase,
catalase, and methionine sulfoxide reductase) and low-
molecular-weight antioxidants (vitamin E, ascorbate, and
GSH) [5]. Macromolecules such as lipids, proteins, and
DNA undergo damage and subsequently cell death mainly2 Oxidative Medicine and Cellular Longevity
by apoptosis when the antioxidant defense network is not
suﬃcient [6].
2. GSHDepletion inPD andAD
The brain is especially vulnerable to free radical damage
because of its high oxygen consumption rate, high con-
tent of lipids, and relative paucity of antioxidant enzymes
compared with other organs [7]. Signiﬁcant biological
changes, related to a condition of oxidative stress, have
been found in brain tissue of individuals aﬀected by PD,
AD, and other diseases [5, 8–11]. In particular, data from
postmortem studies of brains from patients with PD suggest
that oxidative stress plays a role in neural degeneration
of the pigmented dopaminergic neurons in the substantia
nigra pars compacta (SNpc) [12] .T h en o r m a lm e t a b o l i s m
of dopamine can generate free radicals and other ROS.
Furthermore, in the human SNpc the autooxidation of
dopamine leads to neuromelanin and can generate quinone
and semiquinone species and ROS [13]. Finally, enzymatic
oxidation of dopamine catalyzed by monoamine oxidase
leads to formation of H2O2, which can react with Fe2+ and
form the highly reactive radical HO• via the Fenton reaction
[14]. All these unfavorable events contribute to alter the
antioxidant defensessuggesting thattheoxidative stressplays
an important role in PD. The strongest alteration in the
antioxidant defense is a decrease in GSH concentration [15–
17].Accordingtopostmortemstudies,GSHlevelsintheSNpc
of PD patients are remarkably lower than those of healthy
subjects (60% compared to control subjects) while oxidized
glutathione (GSSG) levels are slightly increased [18, 19].
Although GSH is not the only antioxidant molecule reported
to be altered in PD, it is hypothesized that the magnitude
of its depletion is the earliest indicator of nigrostriatal
degeneration [20]. Moreover, striatal DA content and GSH
levels are not altered in areas of the brain other than SNpc,
or in other diseases aﬀecting dopaminergic neurons [21–
24]. GSH loss in PD is also accompanied by a reduction
in mitochondrial complex I activity, which is regionally
selective for the SNpc in PD and does not occur in related
basal ganglia degenerative disorders [25]. These ﬁndings
suggest that decreased nigrostriatal GSH levels can initiate or
facilitateacascadeoffurtheroxidativestresswithconsequent
degeneration of dopaminergic neurons in idiopathic PD
[26, 27].
AD is characterized by the loss of pyramidal neurons in
the hippocampus and cortex, as well as cholinergic neurons
i nt h eb a s a lf o r e b r a i n .T h ee t i o l o g yo fA Di sn o tc o m p l e t e l y
known yet, although there are diﬀerent hallmarks that seem
to play signiﬁcant roles in the disease, such as β-amyloid
(Aβ) deposits, τ-protein aggregation, oxidative damage in
cellular structures, and low levels of acetylcholine (ACh)
[28, 29]. In AD patients there is a strong evidence that Aβ-
associated free radicals and the resultant oxidative stress are
a part of the mechanism that is involved in the pathogenic
cascade that leads to neurodegeneration in AD brain [30].
Furthermore, alterations to GSH metabolism have been
found in these pathological conditions [16]. In this context,
Gu et al. [31] reported that GSH levels are depressed in
AD cingulated cortex and AD substantia innominata, while
Liu et al. [32] found these reduced levels only in red blood
cells of male AD patients. Nevertheless, increased GSH levels
have been observed by Adams et al. [33] in the midbrain
and in the caudate nucleus, while normal GSH contents
have been determined by Perry et al. [34]. Presumably,
dissenting results are due to diﬀerences in techniques or
diﬃculty in sample collection after death of AD patients. In
any case, it has been observed that GSH protects cultured
neurons against oxidative damage resulting from β-peptide
and 4-hydroxynonenal (HNE), a lipid peroxidation product
that is increased in AD [35]. A signiﬁcant decrease in
Cu and signiﬁcant increases in Zn and Fe were found in
AD hippocampus and amygdale, while Cu, Fe, and Zn are
elevated in senile plaques of AD. These metal ions can
catalyze free radical reactions and contribute to oxidative
damage observed in AD brain [36]. GSH protects these areas
through formation of metal complexes via nonenzymatic
reactions and may also be beneﬁcial for normalizing the
adverse eﬀects of iron accumulation in the aging brain [37].
3.AntioxidantNeuroprotectioninPDandAD
Neuroprotective antioxidants are considered a promising
approach to slow down the progression and limit the extent
of neuronal cell loss in neurodegenerative disorders [38–41].
T h e s ea g e n t sw e r ec l a s s i ﬁ e db yB e h la n dM o o s m a n na c c o r d -
ing to their mode of action in (a) compounds that prevent
the formation of free radicals; (b) compounds that chem-
ically interfere with formed free radicals; (c) compounds
which limit the damage extent to the cell by alleviating
the secondary metabolic burden of increased levels of free
radicals [42]. N-acetylcysteine, lipoic acid, GSH, and its thiol
derivatives belong to the last class of neuroprotective antioxi-
dants.Inthiscontext,theGSHsystemisespeciallyimportant
for cellular defense against ROS in brain cells, acting directly
in detoxiﬁcation of radicals in non-enzymatic reactions
and working as a substrate for various peroxidases [43].
Astrocytes appear to play a key role in the GSH metabolism
in the brain since astroglial GSH export is essential for
providing GSH precursor to neurons. Normally astrocytes
release GSH and protect it against oxidation by releasing
a protecting factor into the medium. Astroglial release of
GSH is the ﬁrst step in the supply of the GSH precursor
cysteine to neurons. The extracellular GSH is processed by
γ-glutamyl transpeptidase (γ-GT) and aminopeptidase N
(ApN) to generate the cysteine, which limits the synthesis
of GSH in neurons. Alterations of the release rate of GSH
from astrocytes and reduced activities of the ectoenzymes
may contribute to a lowered antioxidant defense in neurons
and to an increased susceptibility to oxidative stress, both
involved in the progression of neurodegenerative diseases
[44]. Alterations of GSH metabolism in brain have been
found in neurodegenerative disorders as PD and AD [5, 45–
47]. The causes of GSH depletion are not well understood
yet, but their consequences are quite serious. GSH depletion
can inhibit complex I, E1 ubiquitin ligase, and proteasome
activity; it can also exacerbate oxidative stress and activateOxidative Medicine and Cellular Longevity 3
the JNK pathway, leading to an inﬂammatory response.
All these eﬀects cause dopaminergic neuronal death and
accumulation of proteins into Lewy bodies in patients
aﬀected by PD [48]. Furthermore, an emerging evidence
indicates that the total antioxidant capacity (including GSH,
ascorbic acid, uric acid, and bilirubin) has shown to be
reduced by 24% in plasma samples from AD patients [49].
An increased number of mutations in mitochondrial DNA
have been found in AD, such as increased concentrations of
8-hydroxy-2-deoxyguanosine, a marker of oxidative damage
to DNA. These deletions or point mutations, which may
result from oxidative stress, can cause mitochondrial dys-
function and trigger apoptotic cell death. In addition to
DNA damage, several mitochondrial key enzymes involved
in ROS detoxiﬁcation are also aﬀected. In vivo studies on
animal models of AD have also shown the implication of
mitochondriainthediseasepathogenesis[50].Inthisregard,
several groups have focused their eﬀorts on developing
neuroprotective strategies targeting mitochondria. Some of
the major mitochondrial targets used as therapeutics against
ROS-mediated damage are members of the quinone family.
An ubiquinone derivative, mitoquinone mesylate or MitoQ,
has been used to prevent oxidative damage in AD [51].
MitoQ consists of CoQ10 linked to a triphenylphosphonium
ion, which has a positive charge; therefore, it accumulates
in mitochondria, which have a strongly negative mem-
brane potential (about −120mV). More precisely, MitoQ is
adsorbed in the inner mitochondrial membrane facing the
matrix. This ROS-enriched region provides a real potency
to MitoQ. In addition, MitoQ prevents AD-like pathology in
m o u s ec o rti c a ln e u r o n si nc e llc u l t u r e ,a t t e n u a t e sβ-amyloid-
induced neurotoxicity, and prevents increased production of
ROS.
Mitochondrial dysfunction, oxidative stress, glutamate
excitotoxicity, and formation of high-molecular-weight ag-
gregates also deﬁne the most common adult-onset moto-
neuron disease: amyotrophic lateral sclerosis (ALS) caused
by the progressive degeneration of moto-neurons in the
spinal cord, brain stem, and motor cortex [52]. Dominant
mutation in Cu/Zn-superoxide dismutase (SOD1) causes
familial forms of ALS. In order to investigate the role of GSH
in this pathology, knockout mice for the glutamate-cysteine
ligasemodiﬁer(GCLM)subunitwereused.Resultssuggested
that the lack of GCLM signiﬁcantly accelerates disease and
mitochondrial pathology in hSOD1 mice [53].
A promising therapeutic intervention in the above
reported diseases could be the antioxidant neuroprotection
[54]. In this context, the increase of GSH availability in
neuronsisalogicaltherapeuticaltargetinneuralimpairment
related to oxidative stress. Due to the diﬃculty in elevating
GSH directly as described by Zeevalk et al. [55], other
strategies to raise brain levels of this antioxidant have
been investigated [56]. In this paper we will focus on the
medicinal chemistry and technological approaches aimed at
maintaining or restoring GSH levels in PD and AD patients.
Particular attention will be paid to diﬀerent strategies for
increasing GSH levels by supplying GSH codrugs and GSH
nanocarrier systems able to cross the cellular membrane
more easily than GSH.
4.Medicinal-Chemistry-BasedStrategies to
IncreaseGSHLevels
Medicinal-chemistry-based strategies include analogues [57,
58], as well as prodrugs and codrugs approaches [59].
While each of these strategies may be equally promising
to increase GSH levels, this paper will mainly focus on
codrugs approach since the other medicinal-chemistry-
based strategies have been previously discussed [56, 60–
62]. The codrug approach consists in linking, via a covalent
chemical linkage, two diﬀerent pharmacophores with similar
or diﬀerent pharmacological activities in order to improve
physiochemical, biopharmaceutical, and drug delivery prop-
erties of therapeutic agents. The resulting codrug has to
be stable at gastrointestinal level and transported to the
target site of action where it provides the two parent drugs
following hydrolysis [63].
The codrug approach has been used for the treatment of
PD and AD joining antioxidant or chelating molecules with
a therapeutic compound (antiparkinson or anti-alzheimer’s
drugs) [64–66]. In particular, codrugs containing antioxi-
dant molecules such as GSH, N-acetyl-cysteine, methionine,
and cysteinyl derivatives have been synthesized in order
to permit a targeted delivery of antioxidant directly to
speciﬁc groups of neurons where cellular stress is associated
with PD and AD. The dual advantage of these antioxidant
molecules lies in the fact that the antioxidant portion, in
addition to acting as a scavenger directly or indirectly of free
radicals, can be used as a carrier. In fact, GSH and cysteinyl
derivatives can be used as BBB shuttles for delivery of
antiparkinson or ant-Ialzheimer’s drugs since the presence of
GSH transporters at the BBB is well documented [67, 68]. In
this context, the research of new codrugs for the treatment of
PD and AD has gained our attention. L-Dopa-GSH codrugs
(LD-GSH, 1-2), obtained via an amide bond between LD
and the C- and N-terminal GSH, respectively, have been
synthesized and evaluated as potential anti-Parkinson agents
with antioxidant properties (Figure 1)[ 69]. These codrugs
permit a targeted delivery of GSH directly to SNpc neurons
of PD patients and contribute in attenuating the damage
caused by the prooxidant eﬀects of traditional LD therapies.
Codrugs 1-2 showed good stability toward gastrointestinal
simulated ﬂuids and released LD in rat and human plasma
after enzymatic hydrolysis. Furthermore, they prolonged the
plasma LD levels and were able to induce sustained delivery
of dopamine (DA) in rat striatum with respect to equimolar
dose of LD. Taken together, these results demonstrated the
possible therapeutic application of codrugs 1-2 in PD, being
able to protect against the oxidative stress deriving from
autoxidation and the MAO-mediated metabolism of DA
[69].
Later, More and Vince [70] reported two GSH bioconju-
gates (3-4) containing a metabolically stable urea analogue
of GSH resistant to the enzyme γ-GT (Figure 2). The antiox-
idant portion has been covalently joined to the therapeutic
drugs, as DA and adamantine, via a heterodisulﬁde linkage.
This suitable junction is stable in plasma and able to release
DA or adamantine, and the antioxidant portion due to
the abundance of the enzyme disulﬁde reductases in the4 Oxidative Medicine and Cellular Longevity
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Figure 1: Chemical structures of GSH codrugs 1-2.
brain [71]. More importantly, these bioconjugates cross
the BBB through recognition by GSH transporters on the
luminal side of BBB [68]. Studies successfully conﬁrmed
the carrier-mediated transport of conjugates 3-4 in an in
vitro BBB model and their ability to release the active drug
at the target site, thus representing an innovative approach
for the targeted delivery of anti-Parkinson drugs into the
CNS using the GSH transport system [70]. In particular,
the MDCK cell monolayer has been used to study the
bioconjugates 3-4 transport. At concentrationof 100μM,the
transport of bioconjugates 3-4 from the apical to the basal
side was greater than the transport in the reverse direction.
Moreover, to ensure that the codrugs 3-4 were not being
metabolized as they crossed the MDCK cell monolayer, the
integrity of codrugs 3-4 w a sc o n ﬁ r m e db yH P L Cs t u d i e s
[70].TheseexperimentssuccessfullydemonstratedtheGSH-
carrier-mediated transport of the bioconjugates 3-4 in an in
vitro BBB model.
Another bioconjugate that could use the GSH trans-
porters on the luminal side of BBB might be the hybrid 5
(Figure 3).Thismoleculeischaracterizedbythereplacement
of cysteine with methionine in order to obtain stable GSH
analogue at γ-GT [72]. Furthermore, the GSH analogue
has been linked to LD to obtain CNS drug delivery. This
compound was demonstrated to cross unaltered the acidic
environment of the stomach, to be stable enough to be
absorbed from the intestine, to have radical scavenging
activity, and to release LD in human plasma after enzymatic
hydrolysis. Taken together, these data suggest a therapeutic
potential of 5 in pathological events associated with free
radicaldamageanddecreasingDAconcentrationinthebrain
[72].
Recently, Ehrlich et al. [73] designed and synthesized
a library of new GSH codrugs (called UPF peptides)
with powerful hydroxyl radical scavenging activities. They
have been obtained via an amide bond between GSH
and tyrosine derivatives as shown in Figure 4.I np a r t i c -
ular, the enzyme free hydroxyl radical scavenging assay
showed that substitution of γ-glutamyl moiety (UPF1,
4-methoxy-L-tyrosinyl-γ-L-glutamyl-L-cysteinyl-glycine, 6)
with α-glutamyl moiety (UPF17, 4-methoxy-L-tyrosinyl-α-
L-glutamyl-L-cysteinyl-glycine,7)improvedh ydro xylradical
scavenging activity of about 500-fold [74]. UPF1 (6)i sa n
eﬀective and potential agent that diminishes neuronal injury
in global cerebral ischemia [75]; it acts as a free radical
scavenger or a modulator of G-protein in frontocortical
membrane preparations. Although the exact mechanisms of
the protective action of UPF1 still remain unclear, it can
possibly act as a scavenger or a signal molecule increasing
GSH levels or the GSH redox ratio; UPF1 could be a
promising lead for the design of powerful antioxidants for
the treatment of conditions associated with reduced GSH
levels [76]. Unfortunately, the role of UPF peptides for
the treatment of PD has not been studied yet. It could
be interesting to investigate the activity of UPF peptides
in patients aﬀected by PD since these peptides contain the
tyrosine moiety, the metabolic precursor of DA.
Few data are available in the literature about GSH
codrugs for the treatment of AD. We recently synthesized
Ibuprofen-GSH (IBU-GSH, 8) obtained via amide bond
between GSH and IBU, a nonsteroidal anti-inﬂammatory
drug (NSAID) (Figure 5)[ 77]. NSAIDs treatment reduces
AD risk, delays disease progression, and reduces microglia
activation [78]. In particular, Lim et al. [79] reported that
six months of treatment of a transgenic animal model of
AD with IBU resulted in a signiﬁcant reduction of amyloid
plaque burden and total Aβ peptide levels. Furthermore,
IBU treatment led to a reduction of plaque-associated
microglia and a corresponding attenuation in proinﬂam-
matory cytokine levels in brain [80]. Codrug 8 possessed
good stability toward human plasma enzymatic activity and
displayed in vitro free radical scavenging activity in time-
and concentration-dependent manner. More importantly,
it antagonizes the deleterious and cognitive eﬀects of β-
amyloid(1–40) in a rat model for AD, as also conﬁrmed by
behavioral tests of long-term spatial memory. In conclusion,
IBU-GSH might permit targeted delivery of IBU and GSH
directly to neurons, where oxidative stress and inﬂammatory
processes are associated with AD [77].
Almost all the codrugs (1-2, 5, 9–14)h a v eb e e nt e s t e d
for their chemical and enzymatic stabilities in order to check
both their stability in aqueous medium and their sensitivity
towardsenzymaticcleavageinratandhumanplasma(Tables
1 and 2)[ 69, 72, 81]. Stability studies were performed
at 37◦C in isotonic sodium phosphate buﬀer (pH 7.4), in
simulated gastric ﬂuid (SGF, pH 1.3), and in rat and human
plasma diluted to 80% with isotonic sodium phosphate
buﬀer (pH 7.4). All codrugs showed good stability toward
gastrointestinal hydrolysis (t1/2 > 20h) (Table 1). On the
contrary, in rat and human plasma the codrugs (1-2, 5, 9–
14) underwent rapid bioconversion of the codrugs into their
constituents (Table 2).
Sulfur-containing amino acids have gained great atten-
tion as source of thiols for GSH synthesis [82]. A series
of multifunctional thiol codrugs (9–14) were synthesized
to overcome the prooxidant eﬀect associated with LDOxidative Medicine and Cellular Longevity 5
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Figure 2: Chemical structures of GSH codrugs 3-4.
Table 1: Kinetic data for chemical hydrolysis of codrugs 1-2, 5,a n d9–14 at 37◦C.
pH 1.3a pH 7.4a
Compd t1/2 (h) Kobs (h−1) t1/2 (h) Kobs (h−1)
1 20.14 (±0.73) 0.034 (±1.2 ×10
−3)7 .22 (±0.31) 0.096 (±4.1 ×10
−3)
2 28.12 (±1.21) 0.025 (±1.1 ×10
−3)1 2 .23 (±0.49) 0.057 (±2.3 ×10
−3)
5 20.67 (±0.83) 0.094 (±0.3 ×10
−3)1 0 .80 (±0.40) 0.018 (±0.8 ×10
−3)
9 301.0( ±10.5) 0.002 (±0.07 ×10
−3)4 6 .2( ±0.90) 0.015 (±0.3 ×10
−3)
10 290.6( ±5.8) 0.002 (±0.04 ×10
−3)4 8 .0( ±1.70) 0.015 (±0.45 ×10
−3)
11 296.3( ±11.8) 0.002 (±0.08 ×10
−3)3 0 .2( ±1.40) 0.023 (±1.04 ×10
−3)
12 292.1( ±4.4) 0.002 (±0.03 ×10
−3)2 6 .9( ±0.70) 0.026 (±0.65 ×10
−3)
13 292.8( ±8.8) 0.002 (±0.06 ×10
−3)4 8 .50 (±0.70) 0.005 (±0.25 ×10
−3)
14 293.4( ±14.7) 0.002 (±0.1 ×10
−3)2 1 .3( ±0.60) 0.033 (±0.99 ×10
−3)
aValues are means of three experiments, and standard deviation is given in parentheses.
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Figure 3: Chemical structure of GSH hybrid 5.
therapy in parkinsonian models (Figure 6)[ 81]. In this
regard, thiol antioxidants (N-acetyl-L-cysteine, methionine,
dithiothreitol) prevent DA autoxidation, production of
dopamine-melanin, and inhibition of dopamine-induced
apoptosis [83]. Moreover, they increase levels of intracellular
cysteine, the limiting amino acid in GSH biosynthesis, thus
potentiating the natural cellular defense mechanisms against
oxidative damage. The multifunctional codrugs 9-14 proved
to be good radical scavengers. The LD and DA striatal level
proﬁles indicate that codrugs 11 and 12 were able to induce
sustained delivery of both LD and DA in rat striatum with
respect to equimolar doses of LD [82].
In addition, Minelli et al. [84] showed that administra-
tion of codrug 11 to mice treated with Z-ILeu-Glu(OtBu)-
Ala-Leu-CHO (PSI), used as a PD model, resulted in a
reduction in dopaminergic neuronal death and a signiﬁcant
raise in GSH levels. In particular, codrug 11 could control
the LD-induced oxidative stress in primary mesencephalic
cultures and in newborn mice pups since in both cases
GSH content results increased. Using newborn mice pups,
characterized by incomplete formation of BBB, Minelli et
al. [84] found that buthionine-[S,R]-sulfoximine-(BSO-)
mediated GSH depletion prevented the increase of GSH
levels promoted by codrug 11, supporting the role of GSH
for codrug-11-induced protection. To investigate whether
heme oxygenase (HO) activity was related to GSH levels,
ZnPPIX was used as HO inhibitor. Compared to untreated
control, and LD-treated newborn mice, brain GSH levels
were increased by ZnPPIX indicating that HO activity was
not essential to GSH synthesis. An injection of codrug
11 induced a signiﬁcant increase in GSH levels that was
markedly reduced by BSO indicating the essential role of γ-
glutamylcysteine synthetase in increasing GSH brain levels.
Codrug 11 exhibited in vivo protective eﬀect against LD-
induced stress through a mechanism via Nrf2 activation
leading to a decrease in ROS generation and an increase
in GSH. Therefore, this codrug might oﬀer beneﬁts in the
treatment of PD and provide a potential alternative to
LD therapy by avoiding nigrostriatal oxidative degeneration
[84].
Maher et al. [85, 86] demonstrated that the conjugation
of catechins with cysteine generates antioxidant compounds
(15–20) with enhanced neuroprotective activity (Figure 7).
The thiol conjugates 15–20 were active in protecting HT-
22 nerve cells (EC50 b e t w e e n3 6a n d6 5μM) from oxidative6 Oxidative Medicine and Cellular Longevity
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Figure 4: Chemical structures of GSH codrugs 6-7.
Table 2: Rate constants for the hydrolysis of codrugs 1-2, 5,a n d9–14 in 80% rat plasma and 80% human plasma at 37◦C.
Rat plasmaa Human plasmaa
Compd t1/2 (min) Kobs (min−1) t1/2 (min) Kobs (min−1)
1 immediate hydrolysis — 3.2( ±0.1) 0.217 (±6 ×10
−3)
2 2.7( ±0.1) 0.257 (±8 ×10
−3)1 5 .1( ±0.4) 0.046 (±1 ×10
−3)
5 4.7( ±0.1) 0.150 (±0.01) 7.3( ±0.3) 0.100 (±0.01)
9 46.8( ±1.4) 0.010 (±0.20 ×10
−3)6 9 .6( ±1.4) 0.015 (±0.44 ×10
−3)
10 36.6( ±1.6) 0.019 (±0.85 ×10
−3)6 5 .4( ±1.6) 0.011 (±0.26 ×10
−3)
11 115.2( ±11.0) 0.002 (±0.07 ×10
−3) 315.0( ±4.6) 0.006 (±0.24 ×10
−3)
12 93.0( ±10.2) 0.003 (±0.17 ×10
−3) 263.4( ±1.9) 0.007 (±0.14 ×10
−3)
13 55.8( ±10.5) 0.003 (±0.11 ×10
−3) 203.4( ±0.6) 0.030 (±0.75x10 −3)
14 69.6( ±3.5) 0.010 (±0.50 ×10
−3)9 0 .0( ±2.7) 0.008 (±0.24 ×10
−3)
aValues are means of three experiments, standard deviation is given in parentheses.
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Figure 5: Chemical structure of GSH codrug 8.
stress-induced death. Although all the conjugates were able
to scavenge mitochondrial generated ROS inside the cells,
the majority of their neuroprotective activity seems to be
dependent on their ability to maintain GSH levels. These
compounds were able to maintain cellular GSH levels by
enhancing the uptake of cystine/cysteine into cells by a
mechanism that uncouples the uptake from system x−
c ,a
Na+-independent cystine/glutamate antiporter [87]. System
x−
c transports cysteine into cells in a 1:1 exchange with glu-
tamate. The importance of this system for the maintenance
of the GSH levels in cells is demonstrated by the loss of
GSH and subsequent cell death in nerve and other types
of cells following exposure to millimolar concentrations of
extracellular glutamate. Treatments able to maintain GSH
levels, in presence of an induced stress by GSH loss, have a
signiﬁcant potential for the treatment of neurodegenerative
diseases.
5.Technology-Based Strategiesto
IncreaseGSHLevels
Theeﬀectivenessofexogenousantioxidantstoprotecttissues
fromoxidativestressinvivodependsontheantioxidantused,
its physicochemical and biopharmaceutical properties, and
its bioavailability at the site of action [88, 89]. With the
aim of improving the physicochemical, biopharmaceutical
anddrugdeliverypropertiesofneuroprotectiveantioxidants,
the technology-based strategy could be useful for the treat-
ment of several diseases in which oxidative stress plays an
important role [59, 90]. Particularly, this approach could
be adopted in order to selectively deliver antioxidants to
tissues in suﬃcient concentrations to reduce the oxidative
damage. In order to aﬀord neuroprotection and to facilitate
the delivery of GSH across the BBB, several GSH delivery
systems, such as liposomes, nanoparticles, and dendrimers,
were developed.
Liposomes are considered as carrier systems for ther-
apeutically active compounds due to their unique charac-
teristics such as capability of incorporating hydrophilic and
hydrophobic drugs, good compatibility, low toxicity, lack of
immune system activation, and targeted delivery of bioactive
compounds to the site of action [91]. Liposome technology
has been recently used in the treatment of neurodegenerative
diseases. In this context, GSH has been encapsulated in
liposomes in order to replenish intracellular GSH and
provideneuroprotectioninaninvitromodelofPD[92].The
formulation of GSH has been encapsulated in lipid vesiclesOxidative Medicine and Cellular Longevity 7
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made of lecithin and glycerol and then tested on mixed
mesencephalic cultures treated with paraquat plus maneb.
Zeevalk et al. [92] observed that liposomal GSH was taken
up into neurons and astrocytes via an endosomal process,
and subsequently the endosomes containing liposomal-GSH
were fused with lysosomes (Figure 8).
In these conditions, GSH was hydrolyzed and its con-
stituent amino acids (glutamate, cysteine, and glycine)
released from lysosomes could be used for the GSH
biosynthesis. The results obtained by Zeevalk et al. [92]
suggested that this formulation was 100-fold more potent
than nonliposomal-GSH in providing substrates for the
maintenance of intracellular GSH in neuronal cells. More-
over, liposomal-GSH dose-dependently provided complete
neuroprotection of dopaminergic neurons treated with
paraquat plus maneb with an EC50 of 10.5μM ± 1.08. These
ﬁndings suggest that liposomal-GSH represents a promising
therapeuticstrategyforneuronalmaintenanceinpathologies
characterized by GSH depletion.
Nanoparticles (NPs) are solid colloidal particles made of
polymeric materials ranging in size from 1–1000nm. NPs
are used as carrier systems in which the drug is dissolved,
entrapped, encapsulated, adsorbed, or chemically linked to
the surface [93]. The advantages of NPs are high drug-
loading capacity and resistance against chemical and enzy-
matic degradation. Coating NPs with hydrophilic polymer
is a promising strategy in order to prolong their presence in
plasma and the therapeutic eﬀect. The surface modiﬁcation
of NPs can be achieved using polyethylene glycol (PEG)
or polysaccharides such as chitosan, dextran, pectin, and
hyaluronic acid [94, 95]. NPs have been employed for
delivering GSH to CNS. In this regard, a series of NPs
containing GSH (GS-PEG-GS, 21) were prepared with PEGs
of various molecular weights (Figure 9)[ 96]. PEG was
used because of its well-established biocompatibility, low
immunogenicity, low antigenicity, and low toxicity [97].
Unfortunately, GS-PEG-GS nanoparticles were not able
to exert their antioxidant activity because the thiol groups
were consumed during Michael addition. Thus, a disulﬁde
bridge was proposed for antioxidant delivery in order to
release GSH when the pH was low enough to enable thiol
formation. Disulﬁde-linked GSH NPs (GS-SPEGS-SG, 22)
were synthesized and tested on SH-SY5Y cells challenged
with 100μMH 2O2, a compound that induces oxidative8 Oxidative Medicine and Cellular Longevity
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stress. The GS-SPEGS-SG NPs were 100% at protecting SH-
SY5Y cells at 250μM from oxidative stress, while the GS-
PEG-GS did not oﬀer protection [96]. According to these
data, this approach could be employed in treating diseases
typically associated with increased ROS levels.
Chitosan-GSH nanoparticles (CS-GSH NPs) have been
developed by Koo et al. [98] as delivery system for enhancing
stability and bioavailability of GSH. Chitosan (CS) nanode-
livery system oﬀers many advantages: (a) it is not toxic;
(b) it is biodegradable; (c) it is biocompatible; d) it has
good bioadhesibility and water dispersibility [99, 100]. Thus,
CS-GSH was synthesized using a radical polymerization
method,andCS-GSHNPswerepreparedbyionicgelationof
CS-GSH with sodium tripolyphosphate (TPP) (Figure 10).
The resulting NPs showed a good entrapment and loading
eﬃciency. Furthermore, to investigate the CS-GSH NPs
stability under oxidative stress, the eﬀect of the presence of
H2O2 on their thiol groups was evaluated. The reduction
of thiol groups of the CS-GSH NPs under oxidative stress
resulted in being 1.5-fold lower than that of free GSH [98].
These results suggest that CS-GSH NPs could be used as
eﬀective delivery carriers of GSH under oxidative insults, butOxidative Medicine and Cellular Longevity 9
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furtherstudiesonanimalmodelsofPDandADarenecessary
i no r d e rt oe v a l u a t et h e i rt r u ee ﬃcacy.
The use of appropriate nanocarrier systems for GSH may
be useful because they are noninvasive systems and protect
the molecule to be delivered against inactivation mechanism
and clearance. However, they are characterized by limiting
factorsassafetyandtoxicity.Atpresent,fewdataareavailable
about the utilization and human application of nanocarrier
systems for transport across the BBB and CNS delivery.
Thus, the future clinical study of GSH delivery systems for
neurodegenerative diseases is strongly recommended.
6. Conclusions
The drug delivery to CNS is a complex and challenging
task requiring close collaboration of several scientiﬁc areas
includingpharmaceuticalandtechnologicalsciences,biolog-
ical chemistry, and pharmacology. In this context, this paper
has investigated multidisciplinary approaches such as the
codrugandnanocarriersstrategiesthatcouldbeusedtotreat
neurodegenerative disorders associated with GSH deﬁciency.
GSH and cysteinyl codrugs have been designed on the basis
ofcombiningsuitablegroupsoftheantioxidant portionwith
available drugs without altering their inherent pharmacody-
namic properties with improved physiochemical properties
of drugs. This promising approach has also been used to
resolvetheissueslikepermeation,solubilityofdrug,stability,
drug resistance, oral absorption, and brain delivery but still
there are very few well-established candidates that have been
approved for clinical applications.
Novel experimental neuroprotective strategies include
formulations containing GSH, such as nanocarrier systems.
Thisapproachcouldbeadoptedinordertoselectivelydeliver
GSH to tissues in suﬃcient concentrations to reduce the
oxidative damage, but few data are available about clinical
studies.
Although the potential use of these strategies needs
further exhaustive studies, they may oﬀer a promising
therapeutic alternative for reducing the GSH functional loss
related to human diseases such as PD and AD.
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